Most common receptor for atypical antipsychotics is

Correct Answer: B

Rationale: The correct answer is B: D2. Atypical antipsychotics primarily target dopamine D2 receptors, reducing dopamine activity. This helps alleviate symptoms of psychosis with fewer extrapyramidal side effects compared to typical antipsychotics that target D1 receptors. Choice A: D1 receptors are not the primary target for atypical antipsychotics. Choice C: D3 receptors are not the main target, although some atypical antipsychotics may have activity at D3 receptors. Choice D: D4 receptors are not the main target for atypical antipsychotics.

Correct Answer: C

Rationale: The correct answer is C: LTC4. Slow reacting substance of anaphylaxis (SRS-A) is a leukotriene, with LTC4 being the initial form. It plays a key role in allergic reactions by causing bronchoconstriction and increased vascular permeability. PGD2, TXA2, and PGI are not classified as slow reacting substances of anaphylaxis and do not have the same physiological effects as LTC4.

Correct Answer: A

Rationale: Bradykinin is a peptide that causes vasodilation, pain, and an increase in vascular permeability. However, it does not directly cause bronchodilation. This is because bradykinin primarily acts on blood vessels and capillaries, leading to increased blood flow and leakage of fluids, but it does not have a direct effect on the smooth muscle of the bronchioles. Therefore, the correct answer is A. Vasodilation, not bronchodilation. Choices B, C, and D are incorrect because they are all known actions of bradykinin based on its physiological effects.

Correct Answer: A

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Correct Answer: C

Rationale: The correct answer is C (Both). Serotonin agonists like buspirone are used as anxiolytics by acting on serotonin receptors. Sumatriptan is used for migraines by constricting blood vessels and blocking pain pathways. Therefore, both options A and B are correct. Option D is incorrect because both buspirone and sumatriptan have clinical uses as serotonin agonists.